Testing Hypotheses of Covariate-Adaptive Randomized Clinical Trials

Covariate-adaptive designs are often implemented to balance important covariates in clinical trials. However, the theoretical properties of conventional testing hypotheses are usually unknown under covariate-adaptive randomized clinical trials. In the literature, most studies are based on simulations. In this article, we provide theoretical foundation of hypothesis testing under covariate-adaptive designs based on linear models. We derive the asymptotic distributions of the test statistics of testing both treatment effects and the significance of covariates under null and alternative hypotheses. Under a large class of covariate-adaptive designs, (i) the hypothesis testing to compare treatment effects is usually conservative in terms of small Type I error; (ii) the hypothesis testing to compare treatment effects is usually more powerful than complete randomization; and (iii) the hypothesis testing for significance of covariates is still valid. The class includes most of the covariate-adaptive designs in the literature; for example, Pocock and Simon’s marginal procedure, stratified permuted block design, etc. Numerical studies are also performed to assess their corresponding finite sample properties. Supplementary material for this article is available online.

[1]  A. Forsythe,et al.  Validity and power of tests when groups have been balanced for prognostic factors , 1987 .

[2]  Li-Xin Zhang,et al.  Asymptotic properties of covariate-adjusted response-adaptive designs , 2006 .

[3]  Jun Shao,et al.  A theory for testing hypotheses under covariate-adaptive randomization , 2010 .

[4]  L. H. Snyder,et al.  Tests of Simple Mendelian Inheritance in Randomly Collected Data of One and Two Generations , 1939 .

[5]  F. Hu,et al.  Asymptotic properties of covariate-adaptive randomization , 2012, 1210.4666.

[6]  B. Efron Forcing a sequential experiment to be balanced , 1971 .

[7]  B. Griffith,et al.  A randomized trial of inhaled cyclosporine in lung-transplant recipients. , 2006, The New England journal of medicine.

[8]  C. Gridelli,et al.  Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  William F. Rosenberger,et al.  Handling Covariates in the Design of Clinical Trials. , 2008, 1102.3773.

[10]  D R Taves,et al.  Minimization: A new method of assigning patients to treatment and control groups , 1974, Clinical pharmacology and therapeutics.

[11]  F. Hu,et al.  Covariate-adjusted response-adaptive designs for generalized linear models , 2014 .

[12]  R. Simon,et al.  Restricted randomization designs in clinical trials. , 1979, Biometrics.

[13]  S. Pocock,et al.  Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. , 2012, JAMA.

[14]  Feifang Hu,et al.  ST ] 1 7 O ct 2 00 6 ASYMPTOTIC PROPERTIES OF COVARIATE-ADJUSTED ADAPTIVE DESIGNS , 2006 .

[15]  Feifang Hu,et al.  Balancing continuous covariates based on Kernel densities. , 2013, Contemporary clinical trials.

[16]  Dongsheng Tu,et al.  Adjustment of Treatment Effect for Covariates in Clinical Trials: Statistical and Regulatory Issues , 2000 .

[17]  D. Taves,et al.  The use of minimization in clinical trials. , 2010, Contemporary clinical trials.

[18]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[19]  Russ B. Altman,et al.  Clinical evaluation incorporating a personal genome , 2010 .

[20]  Hongyu Zhao,et al.  Adaptive clinical trial designs to detect interaction between treatment and a dichotomous biomarker , 2013 .

[21]  L. J. Wei,et al.  An Application of an Urn Model to the Design of Sequential Controlled Clinical Trials , 1978 .

[22]  C B Begg,et al.  A treatment allocation procedure for sequential clinical trials. , 1980, Biometrics.

[23]  Mikel Aickin,et al.  A Simulation Study of the Validity and Efficiency of Design-Adaptive Allocation to Two Groups in the Regression Situation , 2009, The international journal of biostatistics.

[24]  Zhifu Sun,et al.  Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. , 2010, The Lancet. Oncology.

[25]  M Zelen,et al.  The randomization and stratification of patients to clinical trials. , 1974, Journal of chronic diseases.

[26]  A. Atkinson Optimum biased coin designs for sequential clinical trials with prognostic factors , 1982 .

[27]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[28]  N. Birkett,et al.  Adaptive allocation in randomized controlled trials. , 1985, Controlled clinical trials.

[29]  Stephen B Gruber,et al.  Genetic Variation in 3-Hydroxy-3-Methylglutaryl CoA Reductase Modifies the Chemopreventive Activity of Statins for Colorectal Cancer , 2010, Cancer Prevention Research.

[30]  T. Watts,et al.  Clinical and radiographic evaluation of one-and two-visit endodontic treatment of asymptomatic necrotic teeth with apical periodontitis: a randomized clinical trial , 2008, BDJ.

[31]  S. Kishida,et al.  Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica , 2012, European Spine Journal.

[32]  D P Byar,et al.  The effect of stratified randomization on size and power of statistical tests in clinical trials. , 1978, Journal of chronic diseases.

[33]  J. R. Landis,et al.  The role of prognostic stratification in preventing the bias permitted by random allocation of treatment. , 1976, Journal of chronic diseases.

[34]  William F. Rosenberger,et al.  Implementing Optimal Allocation in Sequential Binary Response Experiments , 2007 .

[35]  Damian McEntegart,et al.  The Pursuit of Balance Using Stratified and Dynamic Randomization Techniques: An Overview , 2003 .

[36]  Richard L. Tweedie,et al.  Markov Chains and Stochastic Stability , 1993, Communications and Control Engineering Series.

[37]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[38]  Yunzhi Lin,et al.  Balancing continuous and categorical baseline covariates in sequential clinical trials using the area between empirical cumulative distribution functions , 2012, Statistics in medicine.

[39]  R. Stephens,et al.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome , 2000, British Journal of Cancer.

[40]  Feifang Hu Statistical issues in trial design and personalized medicine , 2012 .

[41]  Jianhua Hu,et al.  A Unified Family of Covariate-Adjusted Response-Adaptive Designs Based on Efficiency and Ethics , 2015, Journal of the American Statistical Association.